A5005542930- Diabetes Treatment and Management
- Cardiovascular Function and Risk Factors
- Pancreatic function and diabetes
- Intracranial Aneurysms: Treatment and Complications
- Cerebrovascular and Carotid Artery Diseases
- Pancreatitis Pathology and Treatment
- Cardiovascular Health and Disease Prevention
- Metabolism, Diabetes, and Cancer
Royal College of Surgeons in Ireland
2022-2025
Unity Health Toronto
2023-2025
St. Michael's Hospital
2022-2025
Zero to Three
2023
St Michael’s Hospital
2022
Background: Sodium-glucose cotransporter 2 inhibitors have been demonstrated to promote reverse cardiac remodeling in people with diabetes or heart failure. Although it has theorized that sodium-glucose might afford similar benefits without prevalent failure, this not evaluated. We sought determine whether inhibition empagliflozin leads a decrease left ventricular (LV) mass type significant Methods: Between April 2021 and January 2022, 169 individuals, 40 80 years of age, but risk factors...
Abstract Aims The neutrophil‐to‐lymphocyte ratio (NLR) is a marker of systemic inflammation and plays critical role in the assessment prognosis patients with heart failure. EMPA‐HEART CardioLink‐6 trial demonstrated that type 2 diabetes (T2D) coronary artery disease (CAD) treated sodium–glucose transport protein inhibitor for 6 months experienced regression left ventricular mass. Given this, we evaluated relationship baseline NLR cardiac reverse remodelling entire cohort this trial. Methods...
Abstract Aims The duration of type 2 diabetes mellitus (T2DM) is an important determinant severity. EMPA‐HEART CardioLink‐6 trial reported significant left ventricular (LV) mass indexed to body surface area (LVMi) regression in patients treated with the sodium‐glucose cotransporter inhibitor (SGLT2i) empagliflozin for 6 months. This exploratory sub‐analysis same investigated association between T2DM and LVMi regression. Methods results A total 97 individuals coronary artery disease (CAD)...